文献速递免疫规划传染病防控与疫情报告

基于免疫信息学的SARS-CoV-2 B细胞与T细胞表位肽疫苗设计

Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
PubMed 文献 · Vaccine · 2021-01-09

研究采用多种计算生物学方法,从SARS-CoV-2刺突糖蛋白中筛选B细胞与T细胞表位以设计肽疫苗。分析了来自8个国家的8株病毒株的保守序列,鉴定出两个线性B细胞表位、一个结构性B细胞表位及两个T细胞表位,对接模拟显示T细胞表位结合能低且氢键作用强。结论需生物学实验验证。

要点

  • 鉴定出线性B细胞表位SGTNGTKRFDN和ASVYAWNRK及一个结构性B细胞表位。
  • 鉴定出T细胞表位RLFRKSNLK和IPTNFTISV,对接模拟显示强结合潜力。
  • 表位来自刺突糖蛋白保守序列,覆盖8国病毒株,需实验验证。

核心结论

  • 所鉴定的B细胞与T细胞表位为开发针对SARS-CoV-2刺突糖蛋白的探索性疫苗提供了潜在途径,但对所鉴定株需高置信度,尚需生物学实验确认。

研究设计与样本

  • 研究采用多种计算生物学方法,从NCBI数据库提取印度、中国、法国、美国、意大利、澳大利亚、伊朗和巴基斯坦各一株共8株独特病毒株的刺突糖蛋白序列进行分析。

主要发现

  • 通过分析保守序列的表面可及性、抗原性、变异性、保守性、柔性、亲水性、致敏性和毒性等免疫参数,鉴定出两个潜在新型线性B细胞表位SGTNGTKRFDN和ASVYAWNRK、一个结构性B细胞表位以及两个T细胞表位RLFRKSNLK和IPTNFTISV。
  • 对接模拟实验显示上述T细胞表位具有最低自由结合能并表现出强氢键相互作用。

局限性

  • 研究结果需通过生物学实验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 has brought the world to a standstill with a wave of destruction in country after country with tremendous loss of lives and livelihood in advanced to developing nations. Whole world is staring at the prospect of repeated lockdowns with another wave of COVID-19 predicted to hit the world in September of 2020. The second wave is assumed to be even more destructive with severe impact across much of the world. The only way to defeat this pandemic is to quickly develop a safe and effective vaccine against this raging menace and initiate a global vaccination drive. Our study is an attempt to deploy various computational methods to identify B-cell and T-cell epitopes from the spike surface glycoprotein of SARS-COV-2 which have the novel potential for vaccine development against COVID-19. For this we have taken 8 unique strains with one each from India, China, France, USA, Italy, Australia, Iran and Pakistan. The strain data was extracted from NCBI Database. By analyzing the immune parameters like surface accessibility, antigenicity, variability, conservancy, flexibility, hydrophilicity, allergenicity and toxicity of the conserved sequences of spike glycoprotein using various databases and bioinformatics tools, we identified two potential novel linear (SGTNGTKRFDN and ASVYAWNRK) and one structural B-cell epitope as well as two T-cell epitopes (RLFRKSNLK and IPTNFTISV) which can be used as epitope-based peptide vaccines. Docking simulation assay revealed that above T-cell epitopes have minimum free binding energy and showed strong hydrogen bond interaction which strengthened its potential as being a T-cell epitope for the epitope-based novel vaccine against SARS-CoV-2. This study allows us to claim that B-cell and T-cell epitopes mentioned above provide potential pathways for developing an exploratory vaccine against spike surface glycoprotein of SARS-CoV-2 with high confidence for the identified strains. We will need to confirm our findings with biological assays.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Singh J, Malik D, Raina A, et al. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus. Vaccine. 2021. PMID: 33478787. doi:10.1016/j.vaccine.2021.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。